Braide Karin, Kindblom Jon, Thellenberg Karlsson Camilla, Stattin Pär, Hugosson Jonas, Månsson Marianne
Department of Urology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.
BJU Int. 2022 Dec;130(6):799-808. doi: 10.1111/bju.15769. Epub 2022 May 21.
To estimate the long-term risks of severe late toxicities for radiation therapy (RT) following radical prostatectomy (RP) in an unselected nationwide cohort, as severe side-effects are rare but may occur years later.
The study population comprised all men undergoing RP between 1997 and 2016 in the Prostate Cancer database Sweden (PCBaSe) (n = 40 962). By (1:2) matching, two cohorts were created: 2789 men exposed to postoperative RT and 5578 unexposed men with comparable age, comorbidities, and year of surgery. Cumulative incidences and rate ratios were calculated for the following outcomes: symptoms and interventions of the urinary or intestinal tract demanding inpatient care, secondary malignancies, and non-prostate cancer mortality.
The largest differences were seen for late toxicities affecting the urinary tract. The 10-year cumulative incidences among those exposed to postoperative RT vs the RP-only group were: 17.8% vs 10.5% for procedures of the urinary tract (difference 7.3%, 95% confidence interval [CI] 4.4 to 10.3; relative risk [RR] 1.74, 95% CI 1.47 to 2.05); 6.0% vs 1.2% for haematuria (difference 4.8%, 95% CI 3.1 to 6.5; RR 6.50, 95% CI 4.31 to 10.10); and 2.4% vs 1.1% for bladder cancer (difference 1.4%, 95% CI 0.4 to 2.3; RR 2.71, 95% CI 1.72 to 4.33). The groups were similar regarding intestinal toxicity, other secondary malignancies, and non-prostate cancer mortality. Adjustments for preoperative tumour risk factors did not importantly affect the rate ratios.
Severe late toxicity after postoperative RT following RP predominately affects the bladder and can appear many years after RT.
在一个未经过筛选的全国性队列中,评估根治性前列腺切除术后接受放射治疗(RT)出现严重晚期毒性反应的长期风险,因为严重的副作用虽罕见,但可能在数年后发生。
研究人群包括1997年至2016年期间在瑞典前列腺癌数据库(PCBaSe)中接受根治性前列腺切除术的所有男性(n = 40962)。通过(1:2)匹配,创建了两个队列:2789名接受术后放疗的男性和5578名年龄、合并症及手术年份相当的未接受放疗的男性。计算了以下结局的累积发病率和率比:需要住院治疗的泌尿系统或肠道症状及干预措施、继发性恶性肿瘤和非前列腺癌死亡率。
在影响泌尿系统的晚期毒性反应方面差异最大。接受术后放疗组与单纯根治性前列腺切除术组的10年累积发病率分别为:泌尿系统手术为17.8% 对10.5%(差异7.3%,95%置信区间[CI] 4.4至10.3;相对风险[RR] 1.74,95% CI 1.47至2.05);血尿为6.0% 对1.2%(差异4.8%,95% CI 3.1至6.5;RR 6.50,95% CI 4.31至10.10);膀胱癌为2.4% 对1.1%(差异1.4%,95% CI 0.4至2.3;RR 2.71,95% CI 1.72至4.33)。两组在肠道毒性、其他继发性恶性肿瘤和非前列腺癌死亡率方面相似。对术前肿瘤危险因素进行调整后,率比没有受到重要影响。
根治性前列腺切除术后接受放疗后的严重晚期毒性反应主要影响膀胱,且可能在放疗多年后出现。